Physician profile
Randy Wayne Lasut
NPI 1063282994
$2,530.55
in general payments reported to CMS, 2019-2025
32 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $884 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $267.01 | 2024-2025 | |
| Novo Nordisk INC | $250.84 | 2024-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $198.87 | 2024-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $196.35 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $191.55 | 2024-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $176.67 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $128.87 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $94.37 | 2024-2025 | Auvelity |
| Ardelyx, INC. | $93.15 | 2024-2025 | Ibsrela |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.60 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $76.57 | 2024 | Rexulti |
| Boston Scientific Corporation | $73.66 | 2024-2025 | Watchman Flx |
| Verona Pharma, INC. | $67.21 | 2025 | Ohtuvayre |
| Astellas Pharma US INC | $61.49 | 2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.74 | 2024-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.43 | 2024-2025 | Xifaxan, Trulance |
| Viatris Specialty LLC | $57.63 | 2025 | Yupelri |
| Corcept Therapeutics | $51.74 | 2024-2025 | Korlym |
| Lundbeck LLC | $38.93 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $38.25 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $33.66 | 2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Dexcom, INC. | $32.99 | 2024 | Dexcom G6 Transmitter |
| Mylan Specialty L.P. | $31.98 | 2024 | Yupelri |
| Tactile Systems Technology INC | $27.79 | 2025 | Flexitouch Plus, Nimbl |
| Takeda Pharmaceuticals U.S.A., INC. | $18.65 | 2024 | Glassia |
| Novartis Pharmaceuticals Corporation | $18.50 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.51 | 2024 | Xarelto |
| Ucb, INC. | $17.41 | 2024 | Nayzilam |
| Sanofi Pasteur INC. | $14.70 | 2024 | |
| Xeris Pharmaceuticals, INC. | $14.25 | 2024 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $13.73 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.45 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Lasut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.